Bridging the Gap: Pharmacist Experiences Obtaining DEA Licenses - Pharmacy Times
Bridging the Gap: Pharmacist Experiences Obtaining DEA Licenses - Pharmacy Times — DEA update affecting Pharmacy & Controlled Substances.
Aforeworn detected this change in the Pharmacy & Controlled Substances space on September 18, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Pharmacy & Controlled Substances (independent pharmacies, retail chains, compounding pharmacies, long-term-care pharmacies) should confirm how it applies to their specific situation before acting. Aforeworn monitors Pharmacy & Controlled Substances continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed. Regulated niches like Pharmacy & Controlled Substances move faster than most operators can track by hand, which is why Aforeworn watches the official sources for you and flags every material change the moment it appears.
What changed
Bridging the Gap: Pharmacist Experiences Obtaining DEA Licenses - Pharmacy Times
Who it affects
Pharmacy & Controlled Substances (independent pharmacies, retail chains, compounding pharmacies, long-term-care pharmacies)
What you must do
Read the update and assess whether your current setup needs to change.
Deadline
No fixed deadline was published, but changes like this are often enforced quickly — act promptly.
Never miss a change like this again
Aforeworn watches Pharmacy & Controlled Substances around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmacy & Controlled Substances
- Murphy signs bill scheduling tianeptine as Schedule II controlled substance in New Jersey - wrnjradio.com
- Acting U.S attorney: Southern West Virginia pharmacies violated Controlled Substance Act - WV News
- DEA issues 4th extension of telehealth controlled substance flexibilities as debate enters 6th year - fiercehealthcare.com
- Federal jury holds pharmacy chains CVS, Walgreens and Walmart responsible for role in opioid crisis - fiercehealthcare.com
- House Passes Bill To Classify Xylazine As Schedule Iii Controlled Substance - News12 | Bronx